Candel Therapeutics Inc. Common Stock is a biotechnology business based in the US. Candel Therapeutics IncCommon Stock shares (CADL) are listed on the NASDAQ and all prices are listed in US Dollars. Candel Therapeutics IncCommon Stock employs 41 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $6.05 |
|---|---|
| 52-week range | $5.51 - $14.78 |
| 50-day moving average | $8.78 |
| 200-day moving average | $8.93 |
| Wall St. target price | $16.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.30 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.05 from 2022-01-21
| 1 week (2022-01-14) | -3.20% |
|---|---|
| 1 month (2021-12-23) | -27.98% |
| 3 months (2021-10-22) | -37.18% |
| 6 months (2021-07-19) | N/A |
| 1 year (2021-01-19) | N/A |
|---|---|
| 2 years (2020-01-19) | N/A |
| 3 years (2019-01-19) | N/A |
| 5 years (2017-01-19) | N/A |
| Revenue TTM | $125,000 |
|---|---|
| Gross profit TTM | $-8,629,000 |
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $2.20 |
| Market capitalisation | $191.6 million |
TTM: trailing 12 months
We're not expecting Candel Therapeutics IncCommon Stock to pay a dividend over the next 12 months.
Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.